SORT1 and frontotemporal dementia: Most notably, the anti-sortilin IgG1 latozinemab (32) is currently in phase 3 clinical trials for FTD-GRN (clinicaltrials.gov ID: NCT04374136), establishing sortilin targeting as a promising treatment strategy for FTD-GRN.